Clinical Trial Update: Study of Abiraterone Acetate in Subjects With Metastatic Castration Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for Abiraterone Acetate in metastatic castration-resistant prostate cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 3 | Status: COMPLETED